118 related articles for article (PubMed ID: 2126535)
1. Liver-specific contrast agents for MRI.
Stark DD; Elizondo G; Fretz CJ
Invest Radiol; 1990 Sep; 25 Suppl 1():S58. PubMed ID: 2126535
[No Abstract] [Full Text] [Related]
2. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
De Gaspari A; De Cobelli F; Del Maschio A
Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
[TBL] [Abstract][Full Text] [Related]
3. Comparative assessment of gadoxetate disodium, manganese dipyridoxal diphosphate, and superparamagnetic iron oxide for enhancement of the liver in dogs.
Khangure MS; Hua J
Acad Radiol; 1996 Aug; 3 Suppl 2():S458-60. PubMed ID: 8796629
[No Abstract] [Full Text] [Related]
4. Mechanisms of action of liver contrast agents: impact for clinical use.
Clément O; Siauve N; Cuénod CA; Vuillemin-Bodaghi V; Leconte I; Frija G
J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S45-52. PubMed ID: 10608397
[TBL] [Abstract][Full Text] [Related]
5. Preclinical profile of Gd-BOPTA. A liver-specific MRI contrast agent.
Vittadini G; Felder E; Musu C; Tirone P
Invest Radiol; 1990 Sep; 25 Suppl 1():S59-60. PubMed ID: 2283258
[No Abstract] [Full Text] [Related]
6. Diagnosis of fatty liver with MR imaging.
Kreft BP; Tanimoto A; Baba Y; Zhao L; Chen J; Middleton MS; Compton CC; Finn JP; Stark DD
J Magn Reson Imaging; 1992; 2(4):463-71. PubMed ID: 1633400
[TBL] [Abstract][Full Text] [Related]
7. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison.
Fröhlich JM
J Magn Reson Imaging; 2004 Mar; 19(3):375-6; author reply 376. PubMed ID: 14994308
[No Abstract] [Full Text] [Related]
8. Liver-specific MR imaging contrast agents.
Hahn PF; Saini S
Radiol Clin North Am; 1998 Mar; 36(2):287-97. PubMed ID: 9520982
[TBL] [Abstract][Full Text] [Related]
9. Ferrite particles (AMI25). Influence of cirrhosis and chemotherapy on magnetic resonance imaging of metastasis.
Clement O; Schouman-Claeys E; Frija G
Invest Radiol; 1990 Sep; 25 Suppl 1():S61-2. PubMed ID: 2126536
[No Abstract] [Full Text] [Related]
10. Multifocal inflammatory pseudotumor of the liver: dynamic gadolinium-enhanced, ferumoxides-enhanced, and mangafodipir trisodium-enhanced MR imaging findings.
Mortelé KJ; Wiesner W; de Hemptinne B; Elewaut A; Praet M; Ros PR
Eur Radiol; 2002 Feb; 12(2):304-8. PubMed ID: 11870426
[TBL] [Abstract][Full Text] [Related]
11. Hepatic in vivo video microscopic study for evaluating experimental and approved magnetic resonance contrast agents.
Kruskal JB; Lunderquist A; Clouse ME
Invest Radiol; 1994 Jun; 29 Suppl 2():S83-6. PubMed ID: 7928279
[No Abstract] [Full Text] [Related]
12. New contrast agents for imaging the liver.
Helmberger T; Semelka RC
Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):745-66, vi. PubMed ID: 11694436
[TBL] [Abstract][Full Text] [Related]
13. Contrast-enhanced MR imaging of the liver.
Runge VM; Pels Rijcken TH; Davidoff A; Wells JW; Stark DD
J Magn Reson Imaging; 1994; 4(3):281-9. PubMed ID: 8061423
[TBL] [Abstract][Full Text] [Related]
14. Enhanced tumor detection in the presence of fatty liver disease: cell-specific contrast agents.
Kreft BP; Tanimoto A; Baba Y; Zhao L; Finn JP; Stark DD
J Magn Reson Imaging; 1994; 4(3):337-42. PubMed ID: 8061431
[TBL] [Abstract][Full Text] [Related]
15. [Current status of the clinical development of MR contrast media].
Laniado M; Kopp AF
Rofo; 1997 Dec; 167(6):541-50. PubMed ID: 9465947
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of liver-specific MRI contrast agents in rats with hepatitis and cirrhosis.
Kato N; Takahashi M; Ihara S; Tsujimoto T; Miyazawa T
Acad Radiol; 1998 Apr; 5 Suppl 1():S83-5. PubMed ID: 9561051
[No Abstract] [Full Text] [Related]
17. Hepatocyte-targeted MR contrast agents: contrast enhanced detection of liver cancer in diffusely damaged liver.
Tanimoto A; Kuribayashi S
Magn Reson Med Sci; 2005; 4(2):53-60. PubMed ID: 16340158
[TBL] [Abstract][Full Text] [Related]
18. Role of spatial distribution in proton relaxation enhancement by particulate iron oxide.
Tanimoto A; Yuasa Y; Stark DD
Invest Radiol; 1994 Jun; 29 Suppl 2():S78-80. PubMed ID: 7523329
[No Abstract] [Full Text] [Related]
19. Soluble-type hepatobiliary contrast agents for MR imaging.
de Haën C; Gozzini L
J Magn Reson Imaging; 1993; 3(1):179-86. PubMed ID: 8428085
[No Abstract] [Full Text] [Related]
20. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography.
Kim YK; Kwak HS; Han YM; Kim CS
J Comput Assist Tomogr; 2007; 31(5):702-11. PubMed ID: 17895780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
